FindTrial
Sign In

Comparison of efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes Mellitus

To compare the efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes Mellitus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/02/007766
Enrollment
160
Registered
2017-02-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 Diabetes Mellitus

Interventions

Intervention1: teneligliptin: dose 20mg,OD, oral for 6 months Control Intervention1: Vildagliptin: Dose 50mg, BD, oral for 6 months

Sponsors

jawaharlal nehru medical college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed type 2 Diabetes mellitus poorly controlled diabetics on oral hypoglycemic agents

Exclusion criteria

Exclusion criteria: Type 1 DM Patients on insulin Diabetic Ketoacidosis Diabetic Nephropathy CHF Septicaemia Psychotic Patients Pregnancy Known case of HIV/HBs Ag/HCV and immunocompromised patients

Design outcomes

Primary

MeasureTime frame
Glycated Haemoglobin Timepoint: 0,12.24 weeks—

Secondary

MeasureTime frame
Fasting and Post prandial plasma GlucoseTimepoint: 0,6,12,18,24 weeks—

Countries

India

Contacts

Public ContactNIDA RIZVI

Jawaharlal Nehru Medical College and Hospital

ahmad.drjameel@gmail.com7300501166

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026